The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.
James Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis
Sergio Ricci
No relevant relationships to disclose
Robert Winkler
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Valentine Jehl
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marianne Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer